The partnership has launched its new device, Thermoglide. It is a lightweight, portable, FDA-approved device that screens and treats women for cervical cancer in a single sitting
MobileODT, an Israeli FemTech startup focusing on AI-powered cervical screening, in association with India’s digital medical and healthcare solution provider GenWorks, has launched its new device, Thermoglide. It is a lightweight, portable, FDA-approved device that screens and treats women for cervical cancer in a single sitting.
Thermoglide, a battery-operated device, uses the thermo-coagulation technique that destroys tissue using heat. It differs from cryotherapy, another popular approach that uses cold temperatures to remove the tissue. According to the Journal of Obstetrics and Gynaecology Research, thermo-coagulation is as effective and safe as cryotherapy and might be easily applied to treat high-grade cervical lesions.
Dr Priya Ganesh Kumar, Medical Director, SaiNiwaas Health Care & Clinical Advisor Women’s Health, GenWorks, said, “People have been getting good results with Thermoglide in cases of ectropion. After cryotherapy, the patients have a watery discharge for at least three weeks, and they don’t want that. Using cryotherapy in big lesions is also challenging as the technique has limitations. However, Thermoglide can be an effective tool there.”
“According to MobileODT, this device can also cut time by heating quickly, within eight seconds, and remains at 100 degree Celsius, allowing for rapid cervical ablation. With Thermoglide, I can use the heated probe at multiple places, and that too in a shorter time,” added Dr Ganesh.
Leon Boston, CEO, MobileODT said, “ThermoGlide is a necessary tool for every gynecologist due to its versatility, practicality, and ease of use. It can treat precancerous lesions and cervicitis in a simple, painless, quick procedure. We are proud and excited to launch the Thermoglide in India with our partners, GenWorks. India is an important market for us.”